CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

BioMerieux shares rise after Q3 sales beat

By Reuters News

** Shares in BioMérieux BIOX.PA rise 4.4% after the company posted better-than-expected sales in the third quarter

** Q3 sales came at €1,042 million, up 8% year on year organically, above the company's compiled median consensus for sales of €1,007 million and organic growth of 5.9%

** Non-respiratory panels saw a 25% increase year-on-year, helped by demand related to the cyclosporiasis outbreak in the US

** J.P.Morgan notes higher organic growth across all divisions

** "The shares have had a decent run (+16%) into results on easing worries about a FY26 guidance cut and sector rotation but have still underperformed YTD (-18%)," JPM says

** Shares on track for best day since the beginning of August

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.